18:45 , Nov 9, 2018 |  BC Week In Review  |  Company News

AbbVie gains Parkinson’s pipeline from BioArctic

AbbVie Inc. (NYSE:ABBV) gained exclusive, worldwide rights to a pipeline of antibodies targeting α-synuclein (SNCA) to treat Parkinson’s disease for $50 million through an option exercise with BioArctic AB (SSE:BIOA B). The deal is valued...
22:27 , Nov 2, 2018 |  BC Extra  |  Company News

AbbVie gains Parkinson’s pipeline from BioArctic

AbbVie Inc. (NYSE:ABBV) gained exclusive, worldwide rights to a pipeline of antibodies targeting α-synuclein (SNCA) to treat Parkinson’s disease for $50 million through an option exercise with BioArctic AB (SSE:BIOA B). The deal is valued...
20:39 , May 11, 2018 |  BioCentury  |  Emerging Company Profile

Enterin the gut

Enterin Inc. has a new twist on the longstanding Parkinson’s disease target alpha synuclein. The biotech is inhibiting the protein’s accumulation in intestinal nerves rather than in the brain, with the goal of treating constipation...
19:50 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

Prothena discontinues AL amyloidosis candidate

Prothena Corp. plc (NASDAQ:PRTA) discontinued development of amyloid light-chain (AL) amyloidosis candidate NEOD001. The company said the humanized mAb targeting amyloid missed the primary and secondary endpoints in the Phase IIb PRONTO trial, and an...
15:13 , Apr 23, 2018 |  BC Extra  |  Clinical News

Prothena plummets after amyloidosis failure

Prothena Corp. plc (NASDAQ:PRTA) sank $25.34 (69%) to $11.50 on Monday after it discontinued development of amyloid light-chain (AL) amyloidosis candidate NEOD001. The company said the humanized mAb targeting amyloid missed the primary and secondary...
19:50 , Aug 18, 2017 |  BC Week In Review  |  Clinical News

Roche starts Phase II PD trial of PRX002, Prothena receives $30M

Roche (SIX:ROG; OTCQX:RHHBY) began the 2-part, international Phase II PASADENA trial to evaluate 1,500 and 4,500 mg IV PRX002 (RG7935) every 4 weeks in about 300 patients with early Parkinson’s disease (PD). The trial start...
16:32 , Jun 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and cell culture studies suggest α-synuclein inhibitors could help treat melanoma. In patients, tumor levels of α-synuclein were higher in cases of more advanced disease, including metastatic growth phase and vertical...
19:37 , Nov 11, 2016 |  BC Week In Review  |  Clinical News

PRX002: Ph Ib data

A double-blind, placebo-controlled, U.S. Phase Ib trial in 80 PD patients showed that once-monthly 0.3, 1, 3, 10, 30 and 60 mg/kg doses of IV PRX002 for 3 months led to no dose-limiting toxicities (DLTs)...
07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: α-synuclein (SNCA)

Neurology INDICATION: Stroke Mouse studies suggest α-synuclein inhibitors could help treat stroke. In a mouse model of stroke caused by transient middle cerebral artery occlusion, systemic knockout of α-synuclein decreased infarct volume and increased motor...
23:58 , Apr 8, 2015 |  BC Extra  |  Financial News

Follow-on roundup: Dyax, Prothena

Dyax Corp. (NASDAQ:DYAX) and Prothena Corp. plc (NASDAQ:PRTA) raised $321.9 million in follow-on offerings on Wednesday. Dyax raised $199.8 million through the sale of 7.4 million shares at $27 in a deal underwritten by BofA...